Shares of Eli Lilly are moving higher on Tuesday after the company revealed that a recent study, conducted by the company, showed that its weight-loss drug tirzepatide, the active ingredient in its weight-loss drug Zepbound and diabetes drug Mounjaro, cuts diabetes risk by 94%.

Mizuho healthcare equity strategist Jared Holz joins Market Domination to give insight into the data from Eli Lilly and just how much opportunity this drug has for the market and in healthcare.

"I mean, a 94% decline in Type two almost makes me feel like everyone should be on the drug, irrespective of whether they're obese or not. So I think this just continues to open up the market for other indications for the company," says Holz.

He follows that up with: "I think as we move forward here into 2025, I think every single analyst on the Street is going to start to talk up, slash hype, the opportunity in Alzheimer's disease as being another inflammatory indication that's clearly massive, that these drugs could potentially work for. And I think we're going to have data -- I think Novo (NVO) is going to have their data on Alzheimer's disease in the second half of next year, so about a year from now. So I don't think we've ever seen anything like it."

For more expert insight and the latest market action, click here to watch this full episode of Market Domination.

This post was written by Nicholas Jacobino